Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BCD-100,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Shanghai Pharmaceuticals Holding Co.,Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial of An Original Russian Drug for The Treatment of Lung Cancer Starts in China
Details : The BIOCAD and Shanghai Pharmaceuticals Holding joint venture has announced enrollment of patient with treatment prolgolimab in BCD-100-3/DOMAJOR clinical trial of an original anti-PD1 check point inhibitor in patients with non-small cell lung cancer (NS...
Product Name : BCD-100
Product Type : Antibody
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : BCD-100,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Shanghai Pharmaceuticals Holding Co.,Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SARS-CoV-2 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BIOCAD started working on mRNA vaccine against coronavirus
Details : Biocad is developing an mRNA vaccine candidate for COVID-19. Development will be based on previous pipelines for mRNA-oncovaccines creation.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 19, 2020
Lead Product(s) : SARS-CoV-2 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable